Stock Details
MRK is Merck & Co., Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 89.80$. Average daily volumn in 3 months 12.48M. Market cap 235.57B

Stock symbol : MRK. Exchange : NYSE. Currency : USD
Lastest price : 93.15$. Total volume : 871.25k. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Merck & Co., Inc. (MRK)
Last Price

Previous Close93.13
Day Range92.94-93.92
Bid93.17 x 800
Ask93.25 x 1k
Average Volume12.48M
Market Cap235.57B
52 Week Range70.89-95.72
Trailing P/E17.00
Foward P/E12.61
Dividend (Yield %)2.96%
Ex-Dividend Date2022-06-14

Financial Details

According to Merck & Co., Inc.'s financial reports the company's revenue in 2021 were 48.7B an increase( +17.07%) over the years 2020 revenue that were of 41.52B. In 2021 the company's total earnings were 13.05B while total earnings in 2020 were 7.07B( +85.71%).

Loading ...


Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuti... cals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Market Cap:
Total Assets:
Total Cash:

News about "Merck & Co., Inc."


Merck - Seagen deal makes senses even at $250 per share price โ€“ Wells Fargo

Source from : Seeking Alpha - 7 hours ago

Wells Fargo argued on Thursday a buyout offer for Seagen (SGEN) could still make sense at $250 per share after The Wall Street Journal reported that Merck (MRK) was in advanced ...See details»


Merck Reportedly In Advanced Talks To Buy Seagen

Source from : Nasdaq - 16 hours ago

The companies are discussing a price for Seagen above $200 per share, the report specified. Merck and Seagen are seeking to seal a deal on or before the announcement of Merck's second fiscal-quarter ...See details»


Merck in talks to buy cancer biotech Seagen: report

Source from : Fox Business - 16 hours ago

Merck & Co is reportedly in talks to acquire biotech company Seagen Inc. in a nearly $40 billon deal that would add to the company's cancer drug portfolio.See details»


Merck in advanced talks to buy Seagen in nearly $40-billion deal - WSJ

Source from : Reuters on - 17 hours ago

Drugmaker Merck & Co is in advanced talks to buy cancer-focused biotech company Seagen Inc in a deal that could be worth roughly $40 billion or more, the Wall Street Journal reported on Wednesday.See details»

Merck & Co. Inc. (MRK): How investors can get the most out of their investments

Source from : investchronicle - 2 days ago

For the readers interested in the stock health of Merck & Co. Inc. (MRK). It is currently valued at $91.22. When the transactions were called off in the previous session, Stock hit the highs of $92.49 ...See details»


Merck in โ€œadvanced talksโ€ for $40bn Seagen bid; report

Source from : pharmaphorum - 10 hours ago

Rumour that Merck is preparing a bid for Seagen is gathering strength, with latest reports suggesting it could value the cancer biotech at $40bn ...See details»


Merck eyes $40 bln deal for biotech Seagen - WSJ

Source from : Reuters - 9 hours ago

Drugmaker Merck & Co is in advanced talks to buy cancer-focused biotech company Seagen in a deal that could be worth $40 billion or more, the Wall Street Journal reports.See details»

Seagen Shares Rise Premarket as Merck Reportedly Moves Closer to Deal >SGEN

Source from : MarketWatch - 10 hours ago

By Colin Kellaher Shares of Seagen Inc. rose 5% in premarket trading Thursday after The Wall Street Journal reported that Merck & Co. is closing in on ...See details»


Merck Is in Advanced Talks to Acquire Biotech Firm Seagen

Source from : Yahoo Finance - 7 hours ago

Merck & Co. is in advanced talks to acquire Seagen Inc. and could reach an agreement as soon as this month, people familiar with the matter said. Most Read from BloombergNatural Gas Soars 700%, ...See details»


Wedge Capital Management L L P NC Decreases Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Source from : Defense World - 11 days ago

Wedge Capital Management L L P NC decreased its holdings in shares of Merck & Co., Inc. (NYSE:MRK โ€“ Get Rating) by 2.9% during the first quarter, according to the company in its most recent disclosure ...See details»

Merck & Co. Inc. (NYSE: MRK) Share Price Rose Recently, Although Trouble Is Still On The Horizon

Source from : stocksregister - 8 days ago

Merck & Co. Inc. (NYSE:MRK) traded at $92.56 at last check on Wednesday, June 29, made an upward move of 0.73% on its previous dayโ€™s price. Looking at the stock we see that its previous close was $91.See details»


This Acquisition Could Make Merck a Scorching-Hot Buy

Source from : The Motley Fool - 8 days ago

According to reports, Merck is looking at potentially acquiring Seagen. Seagen is a biotech focused on developing innovative treatments for cancer. The deal could help both companies become bigger and ...See details»


8 Analysts Have This to Say About Merck & Co

Source from : Business Insider - 10 days ago

These 8 analysts have an average price target of $96.25 versus the current price of Merck & Co at $95.01, implying upside. Below is a summary of how these 8 analysts rated Merck & ...See details»


A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must)

Source from : Seeking Alpha - 3 days ago

The most recent two hottest potatoes in the biotech arena are Aurinia and Seagen. See why we think AUPH should be on the long side and Merck in the short side.See details»